A Systematic Review and Meta-analysis on Safety and Effectiveness of Extended-interval Dosing of Natalizumab in Patients with Relapsing-remitting Multiple Sclerosis: Is There Any Value in The Cost of Treatment? (PP-08)
Background: Standard-interval dosing (SID) of natalizumab (i.e., 300 mg every 28 days) is approved for patients with relapsing-remitting multiple sclerosis (RRMS). Since patients taking natalizumab are at increased risk of developing progressive multifocal leukoencephalopathy (PML), some neurologist...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Iran University of Medical Sciences
2023-01-01
|
| Series: | Neurology Letters |
| Subjects: | |
| Online Access: | https://www.neurologyletters.com/article_185415_d41d8cd98f00b204e9800998ecf8427e.pdf |